Meta-Analysis of miR-146a Polymorphisms Association with Coronary Artery Diseases and Ischemic Stroke

Mei-Hua Bao 1,*, Yan Xiao 2, Qing-Song Zhang 1, Huai-Qing Luo 1, Ji Luo 1, Juan Zhao 1, Guang-Yi Li 1, Jie Zeng 1 and Jian-Ming Li 1,*

1 Department of Anatomy, Histology and Embryology, Changsha Medical University, Changsha 410219, China; E-Mails: zhangqingsong@whut.edu.cn (Q.-S.Z.); luohuaiqing@163.com (H.-Q.L.); luoji927@163.com (J.L.); zhaojuannanfang2@163.com (J.Z.); liguangyi1977@163.com (G.-Y.L.); zengjie84117@163.com (J.Z.)

2 Qingdao Science & Standard Chemicals Analysing and Testing Co., Ltd., Qingdao 266000, China; E-Mail: y_xiao@sscta.cn

* Authors to whom correspondence should be addressed; E-Mails: mhbao78@163.com (M.-H.B.); ljming0901@sina.com (J.-M.L.); Tel.: +86-731-8488-4488 (M.-H.B.); Fax: +86-731-8849-8866 (M.-H.B.).

Academic Editor: Michael Henein

Received: 21 April 2015 / Accepted: 9 June 2015 / Published: 24 June 2015

Abstract: Coronary artery disease (CAD) and ischemic stroke (IS) are manifestations of atherosclerosis, with a high death rate. miR-146a is a microRNA that participates in the progress of CAD and IS. A single nucleotide polymorphism (SNP) in the precursor of miR-146a, rs2910164, was found to be associated with the risks of CAD and IS. However, the results were inconsistent and inconclusive. A meta-analysis was performed to assess the relationship of rs2910164 and CAD as well as IS susceptibility. The database Pubmed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Chinese National Knowledge Infrastructure (CNKI), and Chinese Biomedical Literature Database (CBM) were searched for related studies. Crude odds ratios with 95% confidence intervals were used to investigate the strength of the association by random- or fixed-effect model. A total of eight studies, with 3138 cases and 3097 controls were identified for the meta-analysis. The results shows that rs2910164 is associated with the risk of CAD significantly in allelic model (OR = 0.86), homozygous model (OR = 0.70), heterozygous model (OR = 0.80) and dominant model (OR = 0.76). The subjects carrying the GG genotype, GG + GC genotype or G allele are at lower risks of CAD. For the susceptibility of IS, there are no significant
associations between rs2910164 and total studies. However, in subgroup analysis by sample size and ethnicity, the GG, GG + GC and G allele of rs2910164 are found to be associated with higher risks of IS in large sample size group and in Koreans, under homozygous and dominant models. In conclusion, the current meta-analysis suggests lower risks of CAD for GG, GG + GC genotype and G allele of rs2910164, while rs2910164 is not associated with the risk of IS. Thus rs2910164 might be recommended as a predictor for susceptibility of CAD, but not IS.

**Keywords:** miR-146a polymorphism; rs2910164; coronary artery disease; ischemic stroke; meta-analysis

### 1. Introduction

Cardiovascular diseases are the major cause of death and disability worldwide. According to the World Health Organization report in 2011, more than 17 million people died of cardiovascular diseases. Coronary artery disease (CAD) is characterized by occlusive epicardial coronary artery stenosis. Ischemic stroke (IS) is a major kind of stroke, which causes a high death rate and adult disability in the world. According to the report of Liu, the annual stroke mortality rate was 120–180 per 100,000 in China [1]. In the United States, stroke ranks as the third leading cause of death [2]. IS has exceeded heart diseases to become the most frequent cause of death. IS and CAD are principal clinical manifestations of atherosclerosis, and have caused a huge burden for society. Previous studies demonstrated that single nucleotide polymorphisms (SNPs) were associated with the risks of CAD and IS [3,4].

MicroRNAs are small, non-coding RNAs which regulate the gene expression in post-transcriptional levels. The regulation effects of microRNAs are obtained by binding to the 3'-UTR of target mRNAs, and lead to degradation or translation repression of target genes. Previous reports predicted that 1/3 of human genes were regulated by microRNAs [5]. Thus, the microRNAs interfere with many physiologic and pathological processes. The changes in the sequences of microRNAs, such as single nucleotide polymorphisms (SNPs), may result in diseases.

miR-146a is a microRNA located at the human chromosome 5q33. Previous studies have demonstrated that miR-146a participates in inflammatory processes, thus interferes with the pathology of cardiovascular diseases [6]. A SNP has been found to exist at the precursor miRNA-146a, which mutates G:U to C:U and results in a low production of mature miR-146a [7]. Studies have reported the relationship between miR-146a polymorphism and susceptibility of coronary artery disease and ischemic stroke. However, the results are somehow inconsistent. For example, some studies demonstrated that miR-146a polymorphism was associated with the risk of CAD and IS [8–12], while others thought it was not [13,14].

Thus it is necessary to make a precise and comprehensive estimation of the association between miR-146a and the risks of CAD and IS. In the present study, eight studies, including 3138 cases and 3097 controls, were included in the meta-analysis.
2. Results

2.1. Characteristics of Eligible Studies

A total of 19 studies were obtained from the literature search after duplicates were removed. Among them, three studies were excluded for irrelevance, two for being reviews, three for being master degree theses and three were only abstracts. Finally, eight studies meeting the criteria were preserved, which included 3138 cases and 3097 controls. The Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow chart is shown in Figure 1 and the information for the selected studies was presented in Table 1.

2.2. Results of Meta-Analysis

The results of meta-analysis for the association between miR-146a (rs2910164) and CAD, IS risks were shown in Table 2 and Figures 2 and 3.

For CAD, significantly decreased risks were found to be associated with rs2910164 under all genetic models, allelic model (OR = 0.86, 95% CI = 0.77–0.96, \(p = 0.01\)), homozygous model (OR = 0.70, 95% CI = 0.55–0.88, \(p = 0.003\)), heterozygous model (OR = 0.80, 95% CI = 0.65–0.98, \(p = 0.03\)) and dominant model (OR = 0.76, 95% CI = 0.63–0.93, \(p = 0.007\)). When we conducted a subgroup analysis by sample size and ethnicity, the same significant associations were observed in the large sample size group and the Chinese group. However, in the small sample size group, a significant decrease in CAD risks was only found in the homozygous model.

On the other hand, no significant association was found between rs2910164 and IS susceptibility in the analysis as a whole. However, subgroup analysis by sample size indicated a significant association between rs2910164 and IS susceptibility in large sample size groups and in Koreans, under homozygous and dominant models (Table 2). No other evident associations between rs2910164 and risk of IS were observed among subgroup analysis by Trial of Org 10,172 in Acute Stroke Treatment (TOAST), gender, smoking, hypertension, diabetes mellitus and hyperlipidemia in the dominant model (Table 3).

![Figure 1. PRISMA flow chart of studies inclusion and exclusion.](image-url)
Table 1. Characteristics of eligible studies included in the meta-analysis.

| Author          | Year | Country | Ethnicity | Disease | Genotyping Methods | Sex Ratio (Male:Female) (Case/Control) | Age (Case/Control) | Quality Score | Sample Size (Case/Control) | GG (Case/Control) | GC (Case/Control) | CC (Case/Control) | HWE of Control |
|-----------------|------|---------|-----------|---------|--------------------|----------------------------------------|-------------------|---------------|-----------------------------|------------------|----------------|----------------|----------------|
| Chen et al.     | 2013 | China   | Asian     | CAD     | Taqman            | 1:1.79/1:1.184                        | 64.57 ± 10.33/64.08 ± 11.21 | 14          | 658/658                     | 181/194          | 305/330         | 172/134         | 0.769          |
| Hamann et al.   | 2014 | German  | Caucasian | CAD     | HRM               | Unavailable                           | Unavailable        | 12          | 206/200                     | 120/117          | 74/73           | 12/10          | 0.748          |
| Ramkaran et al. | 2014 | South Africa | Indian   | CAD     | PCR-RFLP          | 1:0/1:0                               | 37.6 ± 0.40/37.5 ± 0.44 | 12          | 106/100                     | 50/45            | 43/46           | 13/9           | 0.569          |
| Xiong et al.    | 2014 | China   | Asian     | CAD     | PCR-RFLP          | 1:0.661/1:0.601                       | 65.13 ± 11.86/62.59 ± 12.89 | 11          | 295/283                     | 41/61            | 141/125         | 113/97         | 0.086          |
| Huang et al.    | 2015 | China   | Asian     | IS      | Taqman            | 1:0.616/1:0.616                        | 61.0 (54, 68)/63.0 (54, 70) | 14          | 531/531                     | 81/55            | 261/257         | 189/219        | 0.106          |
| Jeon et al.     | 2013 | Korea   | Korean    | IS      | Taqman            | 1:0.441/1:0.496                       | 64.16 ± 11.90/63.14 ± 10.19 | 15          | 678/553                     | 128/76           | 327/266         | 223/211        | 0.589          |
| Liu et al.      | 2013 | China   | Asian     | IS      | PCR-RFLP          | 1:0.608/1:0.581                       | 67.52 ± 10.29/66.34 ± 11.07 | 12          | 296/391                     | 52/77            | 159/198         | 85/116         | 0.65           |
| Zhu et al.      | 2014 | China   | Asian     | IS      | PCR-LDR           | 1:0.688/1:0.685                       | 61.62 ± 0.986/62.05 ± 0.982 | 12          | 368/381                     | 50/64            | 173/185         | 145/132        | 0.952          |

HWE: Hardy-Weinberg equilibrium; CAD: Coronary Artery Disease; HRM: High-resolution melting; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; IS: ischemic stroke.
Table 2. Pooled ORs and 95% CIs of the association between miR-146a (rs2910164) and coronary artery disease (CAD) and ischemic stroke (IS).

| Genetic Model | Overall or Subgroup | CAD | | | IS | |
|---------------|---------------------|-----|-----|---------------------|-----|
|               | n                   | OR (95% CI) | p-Value | F (%) | n | OR (95% CI) | p-Value | F (%) |
| G vs. C       | Overall             | 5   | 0.86 (0.77, 0.96) | 0.01 | 0% | 4 | 1.07 (0.89, 1.29) | 0.45 | 74% |
|               | Large size          | 2   | 0.86 (0.73, 1.00) | 0.05 | NA | 2 | 1.25 (1.11, 1.41) | 0.0003 | 0% |
|               | Small size          | 3   | 0.87 (0.73, 1.03) | 0.10 | 0% | 2 | 0.91 (0.78, 1.05) | 0.20 | 0% |
|               | Chinese             | 2   | 0.83 (0.73, 0.95) | 0.006 | 0% | 3 | 1.02 (0.80, 1.29) | 0.89 | 76% |
|               | Other (Caucasian, Indian, Korean) | 2 | 0.97 (0.75, 0.83) | 0.83 | 0% | 1 | 1.24 (1.06, 1.46) | 0.009 | NA |
| GG vs. CC     | Overall             | 4   | 0.70 (0.55, 0.88) | 0.003 | 0% | 4 | 1.17 (0.78, 1.77) | 0.44 | 76% |
|               | Large size          | 1   | 0.73 (0.54, 0.98) | 0.04 | NA | 2 | 1.64 (1.27, 2.12) | 0.0002 | 0% |
|               | Small size          | 3   | 0.65 (0.44, 0.96) | 0.03 | 0% | 2 | 0.81 (0.59, 1.10) | 0.18 | 0% |
|               | Chinese             | 2   | 0.68 (0.53, 0.88) | 0.003 | 0% | 3 | 1.05 (0.62, 1.77) | 0.87 | 78% |
|               | Other (Caucasian, Indian, Korean) | 2 | 0.81 (0.43, 1.54) | 0.53 | 0% | 1 | 1.59 (1.13, 2.24) | 0.007 | NA |
| GC vs. CC     | Overall             | 4   | 0.80 (0.65, 0.98) | 0.03 | 0% | 4 | 1.08 (0.94, 1.25) | 0.27 | 0% |
|               | Large size          | 1   | 0.72 (0.55, 1.39) | 0.02 | NA | 2 | 1.17 (0.98, 1.40) | 0.09 | 0% |
|               | Small size          | 3   | 0.91 (0.66, 1.25) | 0.56 | 0% | 2 | 0.95 (0.75, 1.22) | 0.71 | 10% |
|               | Chinese             | 2   | 0.80 (0.64, 1.00) | 0.05 | 39% | 3 | 1.04 (0.86, 1.27) | 0.67 | 20% |
|               | Other (Caucasian, Indian, Korean) | 2 | 0.74 (0.39, 1.43) | 0.37 | 0% | 1 | 1.16 (0.91, 1.49) | 0.23 | NA |
| GG/GC vs. CC  | Overall             | 4   | 0.76 (0.63, 0.93) | 0.007 | 0% | 4 | 1.10 (0.90, 1.34) | 0.36 | 54% |
|               | Large size          | 1   | 0.72 (0.56, 0.93) | 0.01 | NA | 2 | 1.26 (1.07, 1.50) | 0.007 | 0% |
|               | Small size          | 3   | 0.83 (0.61, 1.11) | 0.21 | 0% | 2 | 0.91 (0.73, 1.14) | 0.41 | 17% |
|               | Chinese             | 2   | 0.76 (0.62, 0.94) | 0.01 | 0% | 3 | 1.04 (0.79, 1.35) | 0.79 | 60% |
|               | Other (Caucasian, Indian, Korean) | 2 | 0.78 (0.42, 1.45) | 0.43 | 0% | 1 | 1.26 (1.00, 1.59) | 0.05 | NA |

Table 3. Stratified effects of miR-146a (rs2910164) on ischemic stroke risk under dominant genetic model (GG/GC vs. CC).

| Selected Variables | Number of Studies | OR (95% CI) | p-Value | F (%) |
|--------------------|-------------------|-------------|---------|-------|
| TOAST              | LAA               | 3           | 0.80 (0.51, 1.27) | 0.34 | 71% |
|                    | SVD               | 3           | 1.29 (0.90, 1.84) | 0.17 | 58% |
| Gender             | Male              | 2           | 1.06 (0.82, 1.38) | 0.65 | 0% |
|                    | Female            | 2           | 1.16 (0.45, 2.97) | 0.76 | 86% |
| Smoker             | Yes               | 2           | 1.36 (0.91, 2.03) | 0.14 | 0% |
|                    | No                | 2           | 1.09 (0.86, 1.38) | 0.86 | 69% |
| Hypertension       | Yes               | 2           | 0.87 (0.42, 1.82) | 0.72 | 78% |
|                    | No                | 2           | 1.30 (0.97, 1.75) | 0.08 | 0% |
| Diabetes mellitus  | Yes               | 2           | 1.76 (0.96, 3.21) | 0.07 | 0% |
|                    | No                | 2           | 1.25 (0.95, 1.63) | 0.11 | 0% |
| Hyperlipidemia     | Yes               | 2           | 1.16 (0.78, 1.71) | 0.47 | 17% |
|                    | No                | 2           | 1.23 (0.80, 1.88) | 0.34 | 42% |

TOAST: Trial of Org 10172 in Acute Stroke Treatment; LAA, Large artery atherosclerosis; SVD, Small vessel Disease.
Figure 2. Forest plots of odds ratios for the association between microRNA-146a rs2910164 and the risk of CAD. (A) G vs. C; (B) GG vs. CC; (C) GC vs. CC; (D) GG/GC vs. CC.
Figure 3. Forest plots of odds ratios for the association between microRNA-146a rs2910164 and risk of IS. (A) G vs. C; (B) GG vs. CC; (C) GC vs. CC; (D) GG/GC vs. CC.

2.3. Sources of Heterogeneity

For IS, the subgroup analysis indicated the sample size was the source of the heterogeneity among studies ($p = 0.001$ for allelic model; $p = 0.0006$ for homozygous model; and $p = 0.02$ for dominant model) (data not shown). For CAD, there are no significant heterogeneity existing among all studies.
2.4. Sensitivity Analysis

The influence of each study on the pooled ORs and 95% CIs were evaluated by excluding one single study at a time. The corresponding pooled OR was not significantly altered in all genetic models (Figure 4).

Figure 4. The influence of each study by removal of individual studies in China for G vs. C model.

2.5. Publication Bias

We performed the Begg’s funnel plot and Egger’s test to evaluate the publication bias. The p value for Egger’s linear regression tests is shown in Table 4. As the results indicated, no obvious publication bias was observed. And these results were also demonstrated by the shape of funnel plot (not shown).

Table 4. Egger’s linear regression test for funnel plot asymmetries.

| Group         | p-Value |
|---------------|---------|
|               | G vs. C | GG vs. CC | GC vs. CC | GG/GC vs. CC |
| CAD           | 0.240   | 0.137     | 0.965     | 0.967        |
| IS            | 0.110   | 0.191     | 0.420     | 0.276        |

3. Discussion

The main findings of our meta-analysis show that rs2910164 is associated with the risk of CAD significantly in allelic model (OR = 0.86), homozygous model (OR = 0.70), heterozygous model (OR = 0.80) and dominant model (OR = 0.76). The subjects carrying GG genotype, GG + GC genotype or G allele are at lower risks of CAD. For the susceptibility of IS, there are no significant associations between rs2910164 and total studies. However, in subgroup analysis by sample size and ethnicity, the
GG, GG + GC and G allele of rs2910164 are found to be associated with higher risks of IS in large size group and in Koreans, under homozygous and dominant model.

Although a very recent meta-analysis was performed to reveal the relationship of rs2910164 and cardio-cerebrovascular diseases, He et al. [15], they included fewer studies on CAD and IS than those in our meta-analysis. In our meta-analysis, we included two more studies, with 737 cases and 731 controls, for CAD and IS analysis. We further conducted a more comprehensive subgroup analysis for IS by TOAST, gender, smoking, hypertension, diabetes mellitus and hyperlipidemia. Furthermore, we found some surprisingly different results between our meta-analysis and He et al.’s in CAD. Although we found a similar lower CAD risks for G allele vs. C allele, our meta-analysis also demonstrated a lower risks of CAD for GG/GC and GG genotype vs. CC carriers (Figure 2 and Table 2). However, He et al.’s meta-analysis stated a higher risk for GG carriers vs. CC carriers.

In the sensitivity analysis, no significant changes were found after omitting each study one at a time, indicating the relative stability and credibility of the results of our meta-analysis.

We conducted a subgroup analysis by sample size and ethnicity, and observed that rs2910164 was associated with the risks of CAD and IS in the large sample group. However, only one study was included in the large size subgroup in CAD, and two studies were included in IS. We also found a higher risk of IS in Korean for G allele, GG/GC and GG genotypes of miR-146a, and once again, only one study is included in this subgroup. Thus, further studies are needed to confirm these results.

Since no associations were found between rs2910164 and IS, we performed subgroup analysis by TOAST, gender, smoking, hypertension, diabetes mellitus and hyperlipidemia (Table 3). No significant relations were found in all the analyses. But some studies lack sufficient data for the subgroup analysis. For example, the study of Huang et al. [11] lacks TOAST data, while Jeon et al. and Zhu et al. lack gender, smoking, hypertension, hyperlipidemia and diabetes mellitus data [12,16]. Interestingly, in the study of Zhu et al. [16], no significant correlations were found between rs2910164 and overall subjects, though when they divided the patients to LAA and SVD according to TOAST typing, significantly higher frequencies in LAA-caused IS were found in the CC genotype and C allele. However, the results of Zhu et al. [16], focusing on LAA-caused IS was contradictory to the study of Jeon et al. [12]. This may be the result of different target genes, geographical ethnic groups, sample size, etc. Further studies are still needed to resolve this discrepancy.

CAD and IS are both manifestations of atherosclerosis. Most studies included in the present meta-analysis found dyslipidemia in the case group. Previous studies have indicated atherosclerosis as an inflammatory process. Thus, anti-inflammatory treatments decrease the risk of atherosclerosis. miR-146a regulates the NF-κB-induced inflammatory process by targeting interleukin-1 receptor-associated kinase 1 (IRAK-1) and TNF receptor-associated factor 6 (TRAF-6). IRAK-1 and TRAF-6 are upstream regulators of NF-κB activation, and major signal transducers of the Toll-like receptor (TLR) system [9]. The SNP in the pre-miR-146a changed the G to C allele, thus influence the mature miR-146a production, and subsequently influence the inflammatory process of atherosclerosis. Interestingly, the GG, GG + GC genotype and G allele are associated with lower susceptibility of CAD in overall subjects and large sample size group. On the contrary, GG, GG + GC genotype and G allele are related to higher risk of IS in large sample size group. This could be explained by the target gene selection of miR-146a and the pathological differences of these two diseases [10,17–20]. Furthermore, the endothelial dysfunction induced by the inflammatory process is considered to be the first step of atherosclerosis. Further
investigations are needed to reveal whether or not rs2910164 affects endothelial mature miR-146a production and the effects of this variation might have on endothelial functions.

The results of the present meta-analysis should be interpreted carefully because of the following limitations. Firstly, the number of patients was relatively small, and may influence the outcomes. After a very comprehensive literature search from several different databases, only a total of eight studies were included in the present meta-analysis. Among them, four are related to CAD (1265 cases and 1241 controls) and four are related to IS (1873 cases and 1856 controls). The overall OR only indicated the associations between rs2910164 and CAD. However, no associations were found between rs2910164 and IS risk. The second limitation is that the clinicopathological characteristics or disease subtypes are limited in most of these studies. Although we conducted subgroup analysis by clinicopathological characteristics in IS, only half of the included studies provide the necessary data. And for CAD, no such characteristics were available. Thirdly, CAD and IS are both multi-factorial diseases influenced by both genetic and environmental factors. The gene-gene and gene-environment interactions may play important roles in the function of rs2910164, but most studies lack information about environmental exposure and multiple SNPs in miRNA-encoding genes. The fourth limitation lies in the ethnicity of the subjects. Most of the patients were Asians in the present study and this limited the general application of the results to other populations.

In conclusion, the current meta-analysis suggests a decreased risk of CAD for GG, GG + GC genotype and G allele of rs2910164, while rs2910164 is not associated with the risk of IS. Thus rs2910164 might be recommended as a predictor for susceptibility of CAD, but not IS. However, the results of this meta-analysis should be interpreted with caution because of the heterogeneity among study designs. Further study is needed to evaluate the association of rs2910164 and these two diseases, especially in a large sample size, in Caucasians, and with clinicopathological characteristics.

4. Methods

4.1. Publication Search Strategy and Inclusion Criteria

Published studies were systematically searched by Mei-hua Bao and Yan Xiao; the electronic databases Pubmed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Chinese National Knowledge Infrastructure (CNKI) and Chinese Biomedical Literature Database (CBM) were searched for the following terms: “Coronary artery disease (CAD)” or “ischemic stroke (IS)” and (“miR-146a” or “miRNA-146a” or “microRNA-146a”) and (“polymorphism” or “mutation” or “variant” or “SNP” or “single nucleotide polymorphism”), without restriction on language. The deadline for publication was 15 March, 2015. All the results from the databases were screened. First, we screened the title. If the titles fulfilled our criteria, we then screened the abstract. We retrieved the full text if the abstract was interesting. All eligible studies were retrieved manually for other potentially relevant studies from their references. We contacted the authors for related data when they were unavailable in the original publications.

Inclusion Criteria: (a) Case-control design; (b) The association of miR-146a (rs2910164) and CAD or IS risks should be evaluated; (c) The genotype in the control group should be agreed with the Hardy-Weinberg equilibrium (HWE); (d) The data in the publication are sufficient for present
estimation. Studies were excluded if any of the following applies: (1) Repeat publications, abstracts, letters or reviews; (2) Studies not meeting all of the inclusion criteria.

4.2. Data Extraction

We extracted the information from each eligible publication manually by two investigators independently (Qing-song Zhang and Ji Luo). For each study, the extracted information included: First authors’s name, year of publication, country, ethnicity, genotype method, sex ratio, age, source of controls, diseases, genotype numbers of cases and controls. If we encountered discrepancies during data extraction, it was resolved by a consensus achieved by the third author (Jian-ming Li).

4.3. Quality Assessment

The quality of the included studies was evaluated by the following aspects: source of cases, source of controls, specimens used for determining genotypes, total sample size and evidence of HWE. The quality scores ranged from 0–15, higher scores indicating better quality [21]. The quality evaluation was performed by two authors independently (Juan Zhao and Guang-yi Li). Meetings were held to resolve any discrepancies in the assessment process.

4.4. Statistical Methods

χ²-test was used to evaluate the HWE of the control group polymorphism. If \( p < 0.05 \), it was considered to be deviated from HWE. To evaluate the association between miR-146a (rs2910164) and disease (CAD and IS) risk, the crude odds ratio (OR) with 95% confidence interval (CI) was used. The pooled ORs were calculated using genetic model of allelic model (G vs. C), homozygous (GG vs. CC), heterozygous (GC vs. CC) and dominant (GG/GC vs. CC) model, and the statistical significance was determined by the Z-test, and \( p < 0.05 \) was considered to be statistically significant. Subgroup analysis was conducted according to the sample size. Total samples less than 1000 was treated as small, and otherwise as large.

The statistical heterogeneity between studies was evaluated by I-square statistical test, which was not dependent on the number of studies in the meta-analysis [22]. If there was an obvious heterogeneity among the studies (\( I^2 > 50% \)), the random-effects model (the DerSimonian and Laird method) was used for the meta-analysis [23]. Otherwise, the fixed-effect model using the Mantel-Haenszel method was used [24]. Sensitivity analysis was performed to assess the effects of individual study on pooled results and the stability of results. The publication bias was detected with Begg’s funnel plot, and Egger’s linear regression method, and \( p < 0.05 \) was considered to be statistically significant [25]. All statistical analysis was performed using the STATA 12.0 software (StataCorp, College Station, TX, USA) and Revman 5.3.

Acknowledgments

This work was supported by the Key Discipline Construction Program of Hunan Province, National Natural Science Foundation of China (No. 81300231), and Hunan Provincial Natural Science Foundation of China (No. 13JJ4112).
Author Contributions

Conceived of and designed the experiments: Mei-Hua Bao and Jian-Ming Li; Performed the experiments: Mei-Hua Bao, Yan Xiao, Juan Zhao and Guang-Yi Li; Analysis of the data: Qing-Song Zhang, Huai-Qing Luo and Ji Luo; Contributed reagents/materials/analysis tools: Jie Zeng; Wrote the paper: Mei-Hua Bao and Jian-Ming Li.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Liu, L.; Wang, D.; Wong, K.S.; Wang, Y. Stroke and stroke care in China: Huge burden, significant workload, and a national priority. *Stroke* 2011, 42, 3651–3654.
2. Goldstein, L.B.; Adams, R.; Becker, K.; Furberg, C.D.; Gorelick, P.B.; Hademenos, G.; Hill, M.; Howard, G.; Howard, V.J.; Jacobs, B.; et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. *Stroke* 2001, 32, 280–299.
3. Marshall, H.W.; Morrison, L.C.; Wu, L.L. Apolipoprotein polymorphisms pail to define risk of coronary-artery disease-results of a prospective, angiographically controlled-study. *Circulation* 1994, 89, 567–577.
4. Fedele, F.; Mancone, M.; Chilian, W.M.; Severino, P.; Canali, E.; Logan, S.; de Marchis, M.L.; Volterrani, M.; Palmirotta, R.; Guadagni, F. Role of genetic polymorphisms of ion channels in the pathophysiology of coronary microvascular dysfunction and ischemic heart disease. *Basic Res. Cardiol*. 2013, 108, 387.
5. Lewis, B.P.; Burge, C.B.; Bartel, D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 2005, 120, 15–20.
6. Roldan, V.; Arroyo, A.B.; Salloum-Asfar, S.; Manzano-Fernandez, S.; Garcia-Barbera, N.; Marin, F.; Vicente, V.; Gonzalez-Conejero, R.; Martinez, C. Prognostic role of miR146a polymorphisms for cardiovascular events in atrial fibrillation. *Thromb. Haemost.* 2014, 112, 781–788.
7. Jazdzewski, K.; Murray, E.L.; Franssila, K.; Jarzab, B.; Schoenberg, D.R.; de la Chapelle, A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. *Proc. Natl. Acad. Sci. USA* 2008, 105, 7269–7274.
8. Chen, L.; Wu, Y.T. Association of genetic polymorphisms in microRNAs precursor with the risk and prognosis of coronary heart diseases. *J. Xi’an Jiaotong Univ.* 2013, 34, 495–499.
9. Ramkaran, P.; Khan, S.; Phulukdaree, A.; Moodley, D.; Chuturgoon, A.A. miR-146a polymorphism influences levels of miR-146a, IRAK-1, and TRAF-6 in young patients with coronary artery disease. *Cell Biochem. Biophys.* 2014, 68, 259–266.
10. Xiong, X.D.; Cho, M.; Cai, X.P.; Cheng, J.; Jing, X.; Cen, J.M.; Liu, X.; Yang, X.L.; Suh, Y. A common variant in pre-miR-146 is associated with coronary artery disease risk and its mature miRNA expression. *Mutat. Res.* 2014, 761, 15–20.
11. Huang, S.; Zhou, S.; Zhang, Y.; Lv, Z.; Li, S.; Xie, C.; Ke, Y.; Deng, P.; Geng, Y.; Zhang, Q.; et al. Association of the genetic polymorphisms in pre-microRNAs with risk of ischemic stroke in a Chinese population. *PLoS ONE* **2015**, *10*, e0117007.

12. Jeon, Y.J.J.; Kim O.J.; Kim, S.Y.; Oh, S.H.; Oh, D.; Kim, O.J.; Shin, B.S.; Kim, N.K. Association of the miR-146a, miR-149, miR-196a2, and miR-499 polymorphisms with ischemic stroke and silent brain infarction risk Genetic polymorphisms in pre-microRNAs and risk of ischemic stroke in a Chinese population. *Arterioscler. Thromb. Vasc. Biol.* **2013**, *33*, 420–430.

13. Liu, Y.; Ma, Y.; Zhang, B.; Wang, S.X.; Wang, X.M.; Yu, J.M. Genetic polymorphisms in pre-microRNAs and risk of ischemic stroke in a Chinese population. *J. Mol. Neurosci.* **2014**, *52*, 473–480.

14. Hamann, L.; Glaeser, C.; Schulz, S.; Gross, M.; Franke, A.; Nothlings, U.; Schumann, R.R. A micro RNA-146a polymorphism is associated with coronary restenosis. *Int. J. Immunogenet.* **2014**, *41*, 393–396.

15. He, Y.; Yang, J.; Kong, D.; Lin, J.; Xu, C.; Ren, H.; Ouyang, P.; Ding, Y.; Wang, K. Association of miR-146a rs2910164 polymorphism with cardio-cerebrovascular diseases: A systematic review and meta-analysis. *Gene* **2011**, *565*, 171–179.

16. Zhu, R.; Liu, X.; He, Z.; Li, Q. miR-146a and miR-196a2 polymorphisms in patients with ischemic stroke in the northern Chinese Han population. *Neuropsych. Res.* **2014**, *39*, 1709–1716.

17. Guo, M.; Mao, X.; Ji, Q.; Lang, M.; Li, S.; Peng, Y.; Zhou, W.; Xiong, B.; Zeng, Q. miR-146a in PBMCs modulates T1h function in patients with acute coronary syndrome. *Immunol. Cell Biol.* **2010**, *88*, 555–564.

18. Cheng, H.S.; Sivachandran, N.; Lau, A.; Boudreau, E.; Zhao, J.L.; Baltimore, D.; Delgado-Olguin, P.; Cybulsky, M.I.; Fish, J.E. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. *EMBO Mol. Med.* **2013**, *5*, 949–966.

19. El, G.M.; Church, A.; Liu, T.; McCall, C.E. MicroRNA-146a regulates both transcription silencing and translation disruption of TNF-α during TLR4-induced gene reprogramming. *J. Leukoc. Biol.* **2011**, *90*, 509–519.

20. Cui, G.; Wang, H.; Li, R.; Zhang, L.; Li, Z.; Wang, Y.; Hui, R.; Ding, H.; Wang, D.W. Polymorphism of tumor necrosis factor α (TNF-α) gene promoter, circulating TNF-α level, and cardiovascular risk factor for ischemic stroke. *J. Neuroinflamm.* **2012**, *9*, 235.

21. Jiang, D.K.; Wang, W.Z.; Ren, W.H.; Yao, L.; Peng, B.; Yu, L. TP53 Arg72Pro polymorphism and skin cancer risk: A meta-analysis. *J. Investig. Dermatol.* **2011**, *131*, 220–228.

22. Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. *BMJ* **2003**, *327*, 557–560.

23. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. *Control Clin. Trials* **1986**, *7*, 177–188.

24. Mantel, N.; Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. *J. Natl. Cancer Inst.* **1959**, *22*, 719–748.

25. Peters, J.L.; Sutton, A.J.; Jones, D.R.; Abrams, K.R.; Rushton, L. Comparison of two methods to detect publication bias in meta-analysis. *JAMA* **2006**, *295*, 676–680.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).